Stockscreener 앱 받기
2.34
2.50%
-0.06
시간 외 거래:
2.35
0.01
+0.43%
전일 마감가:
$2.40
열려 있는:
$2.37
하루 거래량:
758.54K
Relative Volume:
0.54
시가총액:
$301.10M
수익:
$514.70M
순이익/손실:
$2.72M
주가수익비율:
-14.73
EPS:
-0.1589
순현금흐름:
$17.08M
1주 성능:
-5.26%
1개월 성능:
-2.90%
6개월 성능:
-55.60%
1년 성능:
-25.24%
1일 변동 폭
$2.32
$2.4576
1주일 범위
$2.31
$2.465
52주 변동 폭
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.34 | 310.11M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesEPS Guidance Update - newsline.com
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - PR Newswire
Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ - TradingView
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings Faces Selling Pressure as ORGO Slips to $2.57Oversold Bounce Ideas - newsline.com
Organogenesis Holdings (ORGO) Declines 1.5% as Stock Tests Key Support ZoneFund Manager Survey - The Legal Advocate
Truist initiates Organogenesis stock at Hold on reimbursement shifts - Investing.com UK
Truist initiates Organogenesis stock at Hold on reimbursement shifts By Investing.com - Investing.com India
Truist Initiates Organogenesis Holdings at Hold With $3 Price Target - marketscreener.com
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
- The Legal Advocate
Organogenesis Holdings (ORGO) Edges Lower as Stock Hovers Near Key SupportBullish Percent Index - The Legal Advocate
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings (ORGO) Holds Steady at $2.66 – Consolidation Phase in PlayALMA Signal - The Legal Advocate
ORGO Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational ChallengesEPS Miss Report - newsline.com
ORGO Q1 2026 Earnings: Significant EPS Miss Raises ConcernsEarnings Cycle Outlook - newsline.com
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis Holdings (ORGO) Q1 2026 Earnings Miss by Significant: Key TakeawaysQuarterly Profit Report - newsline.com
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - TradingKey
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds By Investing.com - Investing.com South Africa
BTIG Downgrades Organogenesis(ORGO.US) to Hold Rating - Moomoo
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery - MSN
symbol__ Stock Quote Price and Forecast - CNN
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Organogenesis Q1 Earnings Call Highlights - Barchart.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Report: Exploring A Potential 216% Upside - DirectorsTalk Interviews
Skin Substitute Market Is Going to Boom Rapidly |Organogenesis - openPR.com
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts By Investing.com - Investing.com South Africa
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts - Investing.com Australia
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Organogenesis Holdings Inc 주식 (ORGO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
0.95%
1.13%
자본화:
|
볼륨(24시간):